Cullinan Therapeutics (CGEM) Stock
Emerging company developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Cullinan Therapeutics in October 2026.
Cullinan Oncology Inc (CGEM) is a small-cap biotechnology company focused on developing targeted oncology therapies. The company advances a pipeline across multiple modalities aimed at treating various cancers; as an investor you should expect an emphasis on research and clinical development rather than recurring revenue. With a market capitalisation of around $500.95M, Cullinan sits in the early-to-mid stage of commercialisation life cycles for many biotech firms. Key considerations include the binary nature of clinical trial outcomes, regulatory review timelines, and the potential need for additional financing, which can dilute existing shareholders. The stock can be volatile and is generally suited to investors who can tolerate significant short-term swings and understand biotech development risks. This summary is for educational purposes only and does not constitute personal investment advice; always consider seeking independent financial advice and review company filings before investing.
Cullinan Therapeutics (CGEM) Stock Forecast
Analyst price target, next 12 months
$34.89
+124.7% vs today's $15.53
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Cullinan Therapeutics have a consensus 12-month target of $34.89, above the current price of $15.53.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Cullinan Therapeutics' stock with a target price of $34.89, indicating significant growth potential.
Financial Health
CULLINAN THERAPEUTICS INC shows strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage pipeline
A developing pipeline can offer upside if trials succeed, though outcomes are binary and progress can be slow.
Clinical catalysts
Upcoming readouts or regulatory milestones may move the share price significantly, but they also carry meaningful downside risk.
Funding and partners
Partnerships or financing rounds can accelerate programmes but may dilute shareholders; track filings for updates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
